The latest announcement is out from Tempus AI, Inc. Class A ( (TEM) ).
Tempus AI, Inc. reported significant financial growth for the fourth quarter and full year of 2024, with a 35.8% increase in quarterly revenue and a 49.7% rise in gross profit, driven by its data and services segment. The company completed the acquisition of Ambry Genetics and announced new agreements with major healthcare providers, positioning itself for robust revenue growth and positive Adjusted EBITDA in 2025.
More about Tempus AI, Inc. Class A
Tempus AI, Inc. is a technology company focused on advancing precision medicine through artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians, facilitating personalized patient care and the development of optimal therapeutics.
YTD Price Performance: 98.80%
Average Trading Volume: 9,817,497
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $10.72B
See more data about TEM stock on TipRanks’ Stock Analysis page.